Table 2

Bivariate associations between explanatory variables and polypharmacy status (n=736)

CharacteristicTotal population n (%)No polypharmacy (0–4 drugs) n (%)Polypharmacy (5–9 drugs) n (%)Excessive polypharmacy (≥10 drugs) n (%)p Value*
736341237158
Demographics
Gender
 Male330163 (49.4)101 (30.6)66 (20.0)0.334
 Female406178 (43.8)136 (33.5)92 (22.7)
Age group (years)
 40–49266142 (53.4)74 (27.8)50 (18.8)<0.001
 50–64336160 (47.6)113 (33.6)63 (18.8)
 ≥6513439 (29.1)50 (37.3)45 (33.5)
Level of ID (n=682)
 Mild163100 (61.3)35 (22.1)28 (17.2)
 Moderate316161 (50.9)93 (29.4)62 (19.6)
 Severe/profound20347 (23.1)96 (47.3)60 (29.6)
Residential setting<0.001
 Independent122106 (86.8)18 (14.8)5 (4.1)
 Community group home265151 (57.0)83 (31.3)33 (12.5)
 Residential institution349100 (28.7)136 (39.0)120 (34.4)
 Drug use (mean±SD)5.8 (±4.4)2.1±1.46.7±1.512.6±2.4<0.001
Chronic diseases
 Eye condition*380 (51.6) 265 (69.7) 111(29.2) 74 (19.5)0.032
 Mental health356 (48.0)103 (28.9)142 (39.9)111 (31.2)<0.001
 Neurological268 (35.0)70 (26.4)110 (41.0)88 (32.9)<0.001
 Gastrointestinal198 (26.9)50 (25.2)71 (35.9)77 (38.9)<0.001
 Joint disease153 (20.8)50 (32.7)59 (38.6)44 (28.8)<0.001
 Endocrine disease162 (22.0)57 (35.2)56 (34.6)49 (30.2)<0.001
 Hypertension112 (15.2)32 (28.6)42 (37.5)38 (33.9)<0.001
 Heart disease89 (12.1)32 (36.0)30 (33.7)27 (30.3)0.024
 Reported pain (n=714)33483 (24.9)82 (24.6)73 (21.8)<0.001
  • Bold typeface indicates significant values (p<0.05). *Eye conditions included age-related macular degeneration, glaucoma, cataracts, cataract surgery or other eye disease.